Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity.
Cardiorenal metabolic diseases
Metabolic syndrome
One health
Western diet
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
received:
08
04
2024
accepted:
26
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
5
9
2024
Statut:
epublish
Résumé
Cardiovascular-kidney-metabolic health reflects the interactions between metabolic risk factors, chronic kidney disease, and the cardiovascular system. A growing body of literature suggests that metabolic syndrome (MetS) in individuals of normal weight is associated with a high prevalence of cardiovascular diseases and an increased mortality. The aim of this study was to establish a non-invasive preclinical model of MetS in support of future research focusing on the effects of novel antidiabetic therapies beyond glucose reduction, independent of obesity. Eighteen healthy adult Beagle dogs were fed an isocaloric Western diet (WD) for ten weeks. Biospecimens were collected at baseline (BAS1) and after ten weeks of WD feeding (BAS2) for measurement of blood pressure (BP), serum chemistry, lipoprotein profiling, blood glucose, glucagon, insulin secretion, NT-proBNP, angiotensins, oxidative stress biomarkers, serum, urine, and fecal metabolomics. Differences between BAS1 and BAS2 were analyzed using non-parametric Wilcoxon signed-rank testing. The isocaloric WD model induced significant variations in several markers of MetS, including elevated BP, increased glucose concentrations, and reduced HDL-cholesterol. It also caused an increase in circulating NT-proBNP levels, a decrease in serum bicarbonate, and significant changes in general metabolism, lipids, and biogenic amines. Short-term, isocaloric feeding with a WD in dogs replicated key biological features of MetS while also causing low-grade metabolic acidosis and elevating natriuretic peptides. These findings support the use of the WD canine model for studying the metabolic effects of new antidiabetic therapies independent of obesity.
Identifiants
pubmed: 39237601
doi: 10.1038/s41598-024-71202-y
pii: 10.1038/s41598-024-71202-y
doi:
Substances chimiques
Hypoglycemic Agents
0
Blood Glucose
0
Biomarkers
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20665Subventions
Organisme : CEVA Sante Animale
ID : PO1126151
Organisme : CEVA Sante Animale
ID : PO1126151
Organisme : CEVA Sante Animale
ID : PO1126151
Informations de copyright
© 2024. The Author(s).
Références
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The diabetes prevention program outcomes study. Lancet Diabetes Endocrinol. 3(11), 866–875. https://doi.org/10.1016/S2213-8587(15)00291-0 (2015).
doi: 10.1016/S2213-8587(15)00291-0
pmcid: 4623946
Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html . Accessed 09 Dec 2023.
Birkeland, K. I. et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT-2 inhibitors? A large European observational study. Diabetes Obes. Metab. 21(4), 968–974. https://doi.org/10.1111/dom.13612 (2019).
doi: 10.1111/dom.13612
pubmed: 30537226
pmcid: 6590461
Butler, J. et al. EMPEROR-reduced trial committees and investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: The EMPEROR-reduced trial. Eur. Heart J. 42(13), 1203–1212. https://doi.org/10.1093/eurheartj/ehaa1007 (2021).
doi: 10.1093/eurheartj/ehaa1007
pubmed: 33420498
pmcid: 8014525
Inzucchi, S. E. et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. Diabetes Obes. Metab. 22(4), 631–639. https://doi.org/10.1111/dom.13938 (2020).
doi: 10.1111/dom.13938
pubmed: 31789445
Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389(12), 1069–1084. https://doi.org/10.1056/NEJMoa2306963 (2023).
doi: 10.1056/NEJMoa2306963
pubmed: 37622681
McMurray, J. J. V. et al. The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: Baseline characteristics. Eur. J. Heart Fail. 21(11), 1402–1411. https://doi.org/10.1002/ejhf.1548 (2019).
doi: 10.1002/ejhf.1548
pubmed: 31309699
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(7), 644–657. https://doi.org/10.1056/NEJMoa1611925 (2017).
doi: 10.1056/NEJMoa1611925
pubmed: 28605608
Packer, M. et al. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. Eur. J. Heart Fail. 22(12), 2393–2398. https://doi.org/10.1002/ejhf.2065 (2020).
doi: 10.1002/ejhf.2065
pubmed: 33251659
Persson, F. et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes. Metab. 20(2), 344–351. https://doi.org/10.1111/dom.13077 (2018).
doi: 10.1111/dom.13077
pubmed: 28771923
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128. https://doi.org/10.1056/NEJMoa1504720 (2015).
doi: 10.1056/NEJMoa1504720
pubmed: 26378978
Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: A presidential advisory from the American heart association. Circulation https://doi.org/10.1161/CIR.0000000000001184 (2023).
doi: 10.1161/CIR.0000000000001184
pubmed: 37950677
pmcid: 10330102
Grundy, S. M. et al. American heart association; national heart, lung, and blood institute diagnosis and management of the metabolic syndrome: An American heart association/national heart, lung, and blood institute scientific statement. Circulation 112(17), 2735–2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404 (2005).
doi: 10.1161/CIRCULATIONAHA.105.169404
pubmed: 16157765
Newsome, P. N. & Ambery, P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J. Hepatol. 79, 1557–1565. https://doi.org/10.1016/j.jhep.2023.07.033 (2023).
doi: 10.1016/j.jhep.2023.07.033
pubmed: 37562748
Jacob, J. A. Researchers turn to canine clinical trials to advance cancer therapies. JAMA 315(15), 1550–1552. https://doi.org/10.1001/jama.2016.0082 (2016) (PMID: 27027696).
doi: 10.1001/jama.2016.0082
pubmed: 27027696
Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 110(9), 3507–3512. https://doi.org/10.1073/pnas.1222878110 (2013).
doi: 10.1073/pnas.1222878110
pubmed: 23401516
pmcid: 3587220
Waring, M. J. et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14(7), 475–486. https://doi.org/10.1038/nrd4609 (2015).
doi: 10.1038/nrd4609
pubmed: 26091267
Zushin, P. H., Mukherjee, S. & Wu, J. C. FDA modernization act 2.0: Transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. J. Clin. Invest. 133(21), e175824. https://doi.org/10.1172/JCI175824 (2023).
doi: 10.1172/JCI175824
pubmed: 37909337
pmcid: 10617761
Gilmore, K. M. & Greer, K. A. Why is the dog an ideal model for aging research?. Exp. Gerontol. 71, 14–20. https://doi.org/10.1016/j.exger.2015.08.008 (2015) (Epub 2015 Aug 29 PMID: 26325590).
doi: 10.1016/j.exger.2015.08.008
pubmed: 26325590
Gordon, I., Paoloni, M., Mazcko, C. & Khanna, C. The comparative oncology trials consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 6(10), e1000161. https://doi.org/10.1371/journal.pmed.1000161 (2009).
doi: 10.1371/journal.pmed.1000161
pubmed: 19823573
pmcid: 2753665
Kaeberlein, M., Creevy, K. E. & Promislow, D. E. The dog aging project: Translational geroscience in companion animals. Mamm. Genome 27(7–8), 279–288. https://doi.org/10.1007/s00335-016-9638-7 (2016).
doi: 10.1007/s00335-016-9638-7
pubmed: 27143112
pmcid: 4936929
Kopper, J. J. et al. Harnessing the biology of canine intestinal organoids to heighten understanding of inflammatory bowel disease pathogenesis and accelerate drug discovery: A one health approach. Front. Toxicol. 10(3), 773953. https://doi.org/10.3389/ftox.2021.773953 (2021).
doi: 10.3389/ftox.2021.773953
Masters, A. K. et al. Effects of short-term anti-inflammatory glucocorticoid treatment on clinicopathologic, echocardiographic, and hemodynamic variables in systemically healthy dogs. Am. J. Vet. Res. 79(4), 411–423. https://doi.org/10.2460/ajvr.79.4.411 (2018) (PMID: 29583045).
doi: 10.2460/ajvr.79.4.411
pubmed: 29583045
Sebbag, L. & Mochel, J. P. An eye on the dog as the scientist’s best friend for translational research in ophthalmology: Focus on the ocular surface. Med. Res. Rev. 40(6), 2566–2604. https://doi.org/10.1002/med.21716 (2020).
doi: 10.1002/med.21716
pubmed: 32735080
Xenoulis, P. G. & Steiner, J. M. Lipid metabolism and hyperlipidemia in dogs. Vet. J. 183(1), 12–21. https://doi.org/10.1016/j.tvjl.2008.10.011 (2010).
doi: 10.1016/j.tvjl.2008.10.011
pubmed: 19167915
Kleinert, M. et al. Animal models of obesity and diabetes mellitus. Nat. Rev. Endocrinol. 14(3), 140–162. https://doi.org/10.1038/nrendo.2017.161 (2018).
doi: 10.1038/nrendo.2017.161
pubmed: 29348476
Yin, W. et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J. Lipid Res. 53(1), 51–65. https://doi.org/10.1194/jlr.M019927 (2012).
doi: 10.1194/jlr.M019927
pubmed: 22021650
pmcid: 3243481
Mochel, J. P. et al. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. Eur. J. Pharm. Sci. 1(128), 103–111. https://doi.org/10.1016/j.ejps.2018.11.037 (2019).
doi: 10.1016/j.ejps.2018.11.037
Mochel, J. P. & Danhof, M. Chronobiology and pharmacologic modulation of the renin-angiotensin-aldosterone system in dogs: What have we learned?. Rev. Physiol. Biochem. Pharmacol. 169, 43–69. https://doi.org/10.1007/112_2015_27 (2015) (PMID: 26428686).
doi: 10.1007/112_2015_27
pubmed: 26428686
Mochel, J. P. et al. Pharmacokinetic/pharmacodynamic modeling of renin-angiotensin aldosterone biomarkers following angiotensin-converting enzyme (ACE) inhibition therapy with benazepril in dogs. Pharm. Res. 32(6), 1931–1946. https://doi.org/10.1007/s11095-014-1587-9 (2015).
doi: 10.1007/s11095-014-1587-9
pubmed: 25446774
Schneider, B. et al. Model-based reverse translation between veterinary and human medicine: The one health initiative. CPT Pharmacometrics Syst. Pharmacol. 7(2), 65–68. https://doi.org/10.1002/psp4.12262 (2018).
doi: 10.1002/psp4.12262
pubmed: 29178333
Moinard, A. et al. Effects of high-fat diet at two energetic levels on fecal microbiota, colonic barrier, and metabolic parameters in dogs. Front. Vet. Sci. 25(7), 566282. https://doi.org/10.3389/fvets.2020.566282 (2020).
doi: 10.3389/fvets.2020.566282
Xue, J. et al. A protein- and fiber-rich diet with astaxanthin alleviates high-fat diet-induced obesity in beagles. Front. Nutr. 24(9), 1019615. https://doi.org/10.3389/fnut.2022.1019615 (2022).
doi: 10.3389/fnut.2022.1019615
Peña, C. et al. Effects of low-fat high-fiber diet and mitratapide on body weight reduction, blood pressure and metabolic parameters in obese dogs. J. Vet. Med. Sci. 76(9), 1305–1308. https://doi.org/10.1292/jvms.13-0475 (2014).
doi: 10.1292/jvms.13-0475
pubmed: 24920548
pmcid: 4197164
Sun, H. et al. Different diet energy levels alter body condition, glucolipid metabolism, fecal microbiota and metabolites in adult beagle dogs. Metabolites 13(4), 554. https://doi.org/10.3390/metabo13040554 (2023).
doi: 10.3390/metabo13040554
pubmed: 37110212
pmcid: 10143615
Tvarijonaviciute, A. et al. Obesity-related metabolic dysfunction in dogs: A comparison with human metabolic syndrome. BMC Vet. Res. 28(8), 147. https://doi.org/10.1186/1746-6148-8-147 (2012).
doi: 10.1186/1746-6148-8-147
Vecchiato, C. G. et al. Fecal microbiota and inflammatory and antioxidant status of obese and lean dogs, and the effect of caloric restriction. Front. Microbiol. 12(13), 1050474. https://doi.org/10.3389/fmicb.2022.1050474 (2023).
doi: 10.3389/fmicb.2022.1050474
Romero-Corral, A. et al. Normal weight obesity: A risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur. Heart J. 31(6), 737–746. https://doi.org/10.1093/eurheartj/ehp487 (2010).
doi: 10.1093/eurheartj/ehp487
pubmed: 19933515
Shi, T. H., Wang, B. & Natarajan, S. The influence of metabolic syndrome in predicting mortality risk among US adults: Importance of metabolic syndrome even in adults with normal weight. Prev. Chronic Dis. 21(17), E36. https://doi.org/10.5888/pcd17.200020 (2020).
doi: 10.5888/pcd17.200020
EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol. Dial. Transpl. 37(7), 1317–1329. https://doi.org/10.1093/ndt/gfac040 (2022).
doi: 10.1093/ndt/gfac040
Oyama, K. et al. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur. Heart J. 43(31), 2958–2967. https://doi.org/10.1093/eurheartj/ehab530 (2022) (PMID: 34427295).
doi: 10.1093/eurheartj/ehab530
pubmed: 34427295
Wheeler, D. C. et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol. Dial. Transp. 35(10), 1700–1711. https://doi.org/10.1093/ndt/gfaa234 (2020).
doi: 10.1093/ndt/gfaa234
Adamson, C. et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur. J. Heart Fail. 23(10), 1662–1672. https://doi.org/10.1002/ejhf.2308 (2021).
doi: 10.1002/ejhf.2308
pubmed: 34272791
Iennarella-Servantez, C. A. et al. Diet-induced clinical responsiveness of translational dog model for human western diet (WD)-related disease research. J. Anim. Sci. 99(3), 58–59. https://doi.org/10.1093/jas/skab235.104 (2021).
doi: 10.1093/jas/skab235.104
German, A. J. et al. A simple, reliable tool for owners to assess the body condition of their dog or cat. J. Nutr. 136(7 Suppl), 2031S-2033S. https://doi.org/10.1093/jn/136.7.2031S (2006) (PMID: 16772488).
doi: 10.1093/jn/136.7.2031S
pubmed: 16772488
National Health and Nutrition Examination Survey. (NHANES 2015–2016: Males and Females over 20 years). https://www.ars.usda.gov/northeast-area/beltsville-md-bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/temp-wweia-usual-intake-data-tables/ .
National Research Council. Nutrient Requirements of Dogs and Cats (The National Academies Press, Washington, 2006).
Acierno, M. J. et al. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J. Vet. Intern. Med. 32(6), 1803–1822. https://doi.org/10.1111/jvim.15331 (2018).
doi: 10.1111/jvim.15331
pubmed: 30353952
pmcid: 6271319
Larner, C. D. High performance lipoprotein profiling for cardiovascular risk assessment. PhD thesis, Texas A&M University (2012).
Minamoto, T. et al. Altered lipoprotein profiles in cats with hepatic lipidosis. J. Feline Med. Surg. 21(4), 363–372. https://doi.org/10.1177/1098612X18780060 (2019).
doi: 10.1177/1098612X18780060
pubmed: 29860906
Schneider, B. K. et al. Breakthrough: A first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine. Sci. Rep. 13(1), 3300. https://doi.org/10.1038/s41598-023-30453-x (2023).
doi: 10.1038/s41598-023-30453-x
pubmed: 36843132
pmcid: 9968717
Sotillo, S. et al. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs. Sci. Rep. 13(1), 2684. https://doi.org/10.1038/s41598-023-29771-x (2023).
doi: 10.1038/s41598-023-29771-x
pubmed: 36792677
pmcid: 9932142
Ward, J. L., Chou, Y. Y., Yuan, L., Dorman, K. S. & Mochel, J. P. Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease. J. Vet. Intern. Med. 35(5), 2102–2111. https://doi.org/10.1111/jvim.16236 (2021).
doi: 10.1111/jvim.16236
pubmed: 34387901
pmcid: 8478030
Ward, J. L. et al. Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. J. Vet. Intern. Med. 36(3), 897–909. https://doi.org/10.1111/jvim.16401 (2022).
doi: 10.1111/jvim.16401
pubmed: 35285549
pmcid: 9151484
Domenig, O. et al. Neprilysin is a mediator of alternative renin-angiotensin-system activation in the Murine and human kidney. Sci. Rep. 21(6), 33678. https://doi.org/10.1038/srep33678 (2016).
doi: 10.1038/srep33678
Guo, Z. et al. Measurement of equilibrium angiotensin II in the diagnosis of primary aldosteronism. Clin. Chem. 66(3), 483–492. https://doi.org/10.1093/clinchem/hvaa001 (2020) (PMID: 32068832).
doi: 10.1093/clinchem/hvaa001
pubmed: 32068832
Zoufaly, A. et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 8(11), 1154–1158. https://doi.org/10.1016/S2213-2600(20)30418-5 (2020).
doi: 10.1016/S2213-2600(20)30418-5
pubmed: 33131609
pmcid: 7515587
González-Arostegui, L. G., Muñoz-Prieto, A., Tvarijonaviciute, A., Cerón, J. J. & Rubio, C. P. Measurement of redox biomarkers in the whole blood and red blood cell lysates of dogs. Antioxidants (Basel) 11(2), 424. https://doi.org/10.3390/antiox11020424 (2022).
doi: 10.3390/antiox11020424
pubmed: 35204305
Campos, C., Guzmán, R., López-Fernández, E. & Casado, A. Evaluation of the copper(II) reduction assay using bathocuproinedisulfonic acid disodium salt for the total antioxidant capacity assessment: The CUPRAC-BCS assay. Anal. Biochem. 392(1), 37–44. https://doi.org/10.1016/j.ab.2009.05.024 (2009) (Epub 2009 May 21 PMID: 19464250).
doi: 10.1016/j.ab.2009.05.024
pubmed: 19464250
Rubio, C. P. et al. Validation of three automated assays for total antioxidant capacity determination in canine serum samples. J. Vet. Diagn. Invest. 28(6), 693–698. https://doi.org/10.1177/1040638716664939 (2016).
doi: 10.1177/1040638716664939
pubmed: 27698166
Benzie, I. F. & Strain, J. J. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay. Anal. Biochem. 239(1), 70–76. https://doi.org/10.1006/abio.1996.0292 (1996) (PMID: 8660627).
doi: 10.1006/abio.1996.0292
pubmed: 8660627
Arnao, M. B., Cano, A., Hernández-Ruiz, J., García-Cánovas, F. & Acosta, M. Inhibition by L-ascorbic acid and other antioxidants of the 2.2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) oxidation catalyzed by peroxidase: A new approach for determining total antioxidant status of foods. Anal. Biochem. 236(2), 255–261. https://doi.org/10.1006/abio.1996.0164 (1996).
doi: 10.1006/abio.1996.0164
pubmed: 8660502
Da Costa, C. M., Dos Santos, R. C. C. & Lima, E. S. A simple automated procedure for thiol measurement in human serum samples. J. Bras. Patol. Med. Lab. 42, 345–350. https://doi.org/10.1590/S1676-24442006000500006 (2006).
doi: 10.1590/S1676-24442006000500006
Tvarijonaviciute, A., Tecles, F., Caldin, M., Tasca, S. & Cerón, J. Validation of spectrophotometric assays for serum paraoxonase type-1 measurement in dogs. Am. J. Vet. Res. 73(1), 34–41. https://doi.org/10.2460/ajvr.73.1.34 (2012) (PMID: 22204286).
doi: 10.2460/ajvr.73.1.34
pubmed: 22204286
Kapun, A. P., Salobir, J., Levart, A., Kotnik, T. & Svete, A. N. Oxidative stress markers in canine atopic dermatitis. Res. Vet. Sci. 92(3), 469–470. https://doi.org/10.1016/j.rvsc.2011.04.014 (2012).
doi: 10.1016/j.rvsc.2011.04.014
pubmed: 21601227
Verk, B., Nemec Svete, A., Salobir, J., Rezar, V. & Domanjko, P. A. Markers of oxidative stress in dogs with heart failure. J. Vet. Diagn. Invest. 29(5), 636–644. https://doi.org/10.1177/1040638717711995 (2017).
doi: 10.1177/1040638717711995
pubmed: 28580831
Erel, O. A new automated colorimetric method for measuring total oxidant status. Clin. Biochem. 38(12), 1103–1111. https://doi.org/10.1016/j.clinbiochem.2005.08.008 (2005) (Epub 2005 Oct 7 PMID: 16214125).
doi: 10.1016/j.clinbiochem.2005.08.008
pubmed: 16214125
Tatzber, F., Griebenow, S., Wonisch, W. & Winkler, R. Dual method for the determination of peroxidase activity and total peroxides-iodide leads to a significant increase of peroxidase activity in human sera. Anal. Biochem. 316(2), 147–153. https://doi.org/10.1016/s0003-2697(02)00652-8 (2003) (PMID: 12711334).
doi: 10.1016/s0003-2697(02)00652-8
pubmed: 12711334
Alberti, A., Bolognini, L., Macciantelli, D. & Caratelli, M. The radical cation of N, N-diethyl-para-phenylendiamine: A possible indicator of oxidative stress in biological samples. Res. Chem. Intermed. 26, 253–267. https://doi.org/10.1163/156856700X00769 (2000).
doi: 10.1163/156856700X00769
Rubio, C. P. et al. Stability of biomarkers of oxidative stress in canine serum. Res. Vet. Sci. 121, 85–93. https://doi.org/10.1016/j.rvsc.2018.09.007 (2018).
doi: 10.1016/j.rvsc.2018.09.007
pubmed: 30359815
Witko-Sarsat, V. et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 49(5), 1304–1313. https://doi.org/10.1038/ki.1996.186 (1996) (PMID: 8731095).
doi: 10.1038/ki.1996.186
pubmed: 8731095
Matyash, V., Liebisch, G., Kurzchalia, T. V., Shevchenko, A. & Schwudke, D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J. Lipid Res. 49(5), 1137–1146. https://doi.org/10.1194/jlr.D700041-JLR200 (2008).
doi: 10.1194/jlr.D700041-JLR200
pubmed: 18281723
pmcid: 2311442
Sumner, L. W. et al. Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI). Metabolomics 3(3), 211–221. https://doi.org/10.1007/s11306-007-0082-2 (2007).
doi: 10.1007/s11306-007-0082-2
pubmed: 24039616
pmcid: 3772505
Adutwum, L. A., de la Mata, A. P., Bean, H. D., Hill, J. E. & Harynuk, J. J. Estimation of start and stop numbers for cluster resolution feature selection algorithm: An empirical approach using null distribution analysis of Fisher ratios. Anal. Bioanal. Chem. 409(28), 6699–6708. https://doi.org/10.1007/s00216-017-0628-8 (2017).
doi: 10.1007/s00216-017-0628-8
pubmed: 28963623
pmcid: 9677961
Sinkov, N. A. & Harynuk, J. J. Cluster resolution: A metric for automated, objective and optimized feature selection in chemometric modeling. Talanta 83(4), 1079–1087. https://doi.org/10.1016/j.talanta.2010.10.025 (2011).
doi: 10.1016/j.talanta.2010.10.025
pubmed: 21215842
Lyu, Y. et al. Differences in metabolic profiles of healthy dogs fed a high-fat vs. a high-starch diet. Front. Vet. Sci. 9, 801863. https://doi.org/10.3389/fvets.2022.801863 (2022).
doi: 10.3389/fvets.2022.801863
pubmed: 35252418
pmcid: 8891928
Cavaghan, M. K., Ehrmann, D. A. & Polonsky, K. S. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J. Clin. Invest. 106(3), 329–333. https://doi.org/10.1172/JCI10761 (2000).
doi: 10.1172/JCI10761
pubmed: 10930434
pmcid: 314336
Rix, I., Nexøe-Larsen, C., Bergmann, N. C., Lund, A. & Knop, F. K. Glucagon Physiology. In: Feingold, K. R., Anawalt, B., Blackman, M. R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W. W., Dhatariya, K., Dungan, K., Hofland, J., Kalra, S., Kaltsas, G., Kapoor, N., Koch, C., Kopp, P., Korbonits, M., Kovacs, C. S., Kuohung, W., Laferrère, B., Levy, M., McGee, E. A., McLachlan, R., New, M., Purnell, J., Sahay, R., Shah, A. S., Singer, F., Sperling, M. A., Stratakis, C. A., Trence, D. L. & Wilson, D. P., (eds). South Dartmouth (MA): MDText.com, Inc. (2000).
Burger, M. & Schaller, D. J. Metabolic Acidosis. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID: 29489167 (2023).
Wieërs, M. L. A. J., Beynon-Cobb, B., Visser, W. J. & Attaye, I. Dietary acid load in health and disease. Pflugers Arch. 476(4), 427–443. https://doi.org/10.1007/s00424-024-02910-7 (2024).
doi: 10.1007/s00424-024-02910-7
pubmed: 38282081
pmcid: 11006742
Sharma, S., Hashmi, M. F. & Aggarwal, S. Hyperchloremic Acidosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2023).
Bamgbola, O. F. Review of the pathophysiologic and clinical aspects of hypokalemia in children and young adults: An Update. Curr. Treat Options Pediatr. 8(3), 96–114. https://doi.org/10.1007/s40746-022-00240-3 (2022).
doi: 10.1007/s40746-022-00240-3
pubmed: 37521171
pmcid: 9115742
Batlle, D. et al. Proximal renal tubular acidosis and hypophosphatemia induced by arginine. Adv. Exp. Med. Biol. 151, 239–249. https://doi.org/10.1007/978-1-4684-4259-5_30 (1982) (PMID: 6817609).
doi: 10.1007/978-1-4684-4259-5_30
pubmed: 6817609
Vasquez-Rios, G., Westrich, D. J. Jr., Philip, I., Edwards, J. C. & Shieh, S. Distal renal tubular acidosis and severe hypokalemia: A case report and review of the literature. J. Med. Case Rep. 13(1), 103. https://doi.org/10.1186/s13256-019-2056-1 (2019).
doi: 10.1186/s13256-019-2056-1
pubmed: 31023369
pmcid: 6485144
Lambert, D. C., Kane, J., Slaton, A. & Abramowitz, M. K. Associations of metabolic syndrome and abdominal obesity with anion gap metabolic acidosis among US adults. Kidney360 3(11), 1842–1851. https://doi.org/10.34067/KID.0002402022 (2022).
doi: 10.34067/KID.0002402022
pubmed: 36514392
pmcid: 9717647
Stoian, M. & Stoica, V. The role of distubances of phosphate metabolism in metabolic syndrome. Maedica (Bucur) 9(3), 255–260 (2014).
pubmed: 25705287
Sun, K. et al. Serum potassium level is associated with metabolic syndrome: A population-based study. Clin. Nutr. 33(3), 521–527. https://doi.org/10.1016/j.clnu.2013.07.010 (2014).
doi: 10.1016/j.clnu.2013.07.010
pubmed: 23910935
Kalaitzidis, R., Tsimihodimos, V., Bairaktari, E., Siamopoulos, K. C. & Elisaf, M. Disturbances of phosphate metabolism: Another feature of metabolic syndrome. Am. J. Kidney Dis. 45(5), 851–858. https://doi.org/10.1053/j.ajkd.2005.01.005 (2005) (PMID: 15861350).
doi: 10.1053/j.ajkd.2005.01.005
pubmed: 15861350
Shimodaira, M., Okaniwa, S. & Nakayama, T. Reduced serum phosphorus levels were associated with metabolic syndrome in men but not in women: A cross-sectional study among the Japanese population. Ann. Nutr. Metab. 71(3–4), 150–156. https://doi.org/10.1159/000480354 (2017).
doi: 10.1159/000480354
pubmed: 28881349
Tropf, M., Nelson, O. L., Lee, P. M. & Weng, H. Y. Cardiac and metabolic variables in obese dogs. J. Vet. Intern. Med. 31(4), 1000–1007. https://doi.org/10.1111/jvim.14775 (2017).
doi: 10.1111/jvim.14775
pubmed: 28608635
pmcid: 5508341
Hussain, A. et al. Association of NT-ProBNP, blood pressure, and cardiovascular events: The ARIC study. J. Am. Coll. Cardiol. 77(5), 559–571. https://doi.org/10.1016/j.jacc.2020.11.063 (2021).
doi: 10.1016/j.jacc.2020.11.063
pubmed: 33538254
pmcid: 7945981
Jang, I. S., Yoon, W. K. & Choi, E. W. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B. Ir. Vet. J. 76(1), 3. https://doi.org/10.1186/s13620-023-00233-0 (2023).
doi: 10.1186/s13620-023-00233-0
pubmed: 36755290
pmcid: 9906826
Bayes-Genis, A. et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the heart failure association of the ESC. Eur. J. Heart Fail. https://doi.org/10.1002/ejhf.3036 (2023).
doi: 10.1002/ejhf.3036
pubmed: 38059343
Singletary, G. E., Morris, N. A., Lynne O’Sullivan, M., Gordon, S. G. & Oyama, M. A. Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman Pinschers. J. Vet. Intern. Med. 26(6), 1330–1336. https://doi.org/10.1111/j.1939-1676.2012.1000.x (2012).
doi: 10.1111/j.1939-1676.2012.1000.x
pubmed: 22998090
Wilshaw, J. et al. Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease. J. Vet. Intern. Med. 35(2), 755–770. https://doi.org/10.1111/jvim.16083 (2021).
doi: 10.1111/jvim.16083
pubmed: 33645846
pmcid: 7995403
Akinkuolie, A. O., Paynter, N. P., Padmanabhan, L. & Mora, S. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ. Cardiovasc. Qual. Outcomes 7(1), 55–63. https://doi.org/10.1161/CIRCOUTCOMES.113.000675 (2014).
doi: 10.1161/CIRCOUTCOMES.113.000675
pubmed: 24248942
Superko, H. R. et al. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J. Clin. Lipidol. 6(6), 496–523. https://doi.org/10.1016/j.jacl.2012.03.001 (2012).
doi: 10.1016/j.jacl.2012.03.001
pubmed: 23312047
Duan, R. et al. Estimation of the LDL subclasses in ischemic stroke as a risk factor in a Chinese population. BMC Neurol. 20(1), 414. https://doi.org/10.1186/s12883-020-01989-6 (2020).
doi: 10.1186/s12883-020-01989-6
pubmed: 33183255
pmcid: 7664065
Lahm Cardoso, J. M. et al. Blood pressure, serum glucose, cholesterol, and triglycerides in dogs with different body scores. Vet. Med. Int. 2016, 8675283. https://doi.org/10.1155/2016/8675283 (2016).
doi: 10.1155/2016/8675283
Aleksandrova, K., Koelman, L. & Rodrigues, C. E. Dietary patterns and biomarkers of oxidative stress and inflammation: A systematic review of observational and intervention studies. Redox Biol. 42, 101869. https://doi.org/10.1016/j.redox.2021.101869 (2021).
doi: 10.1016/j.redox.2021.101869
pubmed: 33541846
pmcid: 8113044
Boden, G. et al. Excessive caloric intake acutely causes oxidative stress, GLUT4 carbonylation, and insulin resistance in healthy men. Sci. Transl. Med. 7(304), 304re7. https://doi.org/10.1126/scitranslmed.aac4765 (2015).
doi: 10.1126/scitranslmed.aac4765
pubmed: 26355033
pmcid: 5600191
Matsuzawa-Nagata, N. et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism 57(8), 1071–1077. https://doi.org/10.1016/j.metabol.2008.03.010 (2008) (PMID: 18640384).
doi: 10.1016/j.metabol.2008.03.010
pubmed: 18640384
Chiofalo, B. et al. Effects of dietary protein and fat concentrations on hormonal and oxidative blood stress biomarkers in guide dogs during training. J. Vet. Behav. 37, 86–92. https://doi.org/10.1016/j.jveb.2019.12.003 (2020).
doi: 10.1016/j.jveb.2019.12.003
Qu, W. et al. Profound perturbation in the metabolome of a canine obesity and metabolic disorder model. Front. Endocrinol. (Lausanne) 19(13), 849060. https://doi.org/10.3389/fendo.2022.849060 (2022).
doi: 10.3389/fendo.2022.849060
Amjad, S. et al. Role of NAD
doi: 10.1016/j.molmet.2021.101195
pubmed: 33609766
pmcid: 7973386
Surjana, D., Halliday, G. M. & Damian, D. L. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J. Nucleic Acids. 25(2010), 157591. https://doi.org/10.4061/2010/157591 (2010).
doi: 10.4061/2010/157591
Frühbeck, G., Méndez-Giménez, L., Fernández-Formoso, J. A., Fernández, S. & Rodríguez, A. Regulation of adipocyte lipolysis. Nutr. Res. Rev. 27(1), 63–93. https://doi.org/10.1017/S095442241400002X (2014) (Epub 2014 May 28 PMID: 24872083).
doi: 10.1017/S095442241400002X
pubmed: 24872083
Bánhegyi, G. & Loewus, F. A. Ascorbic acid catabolism: Breakdown pathways in animals and plants. In Vitamin C, Function and Biochemistry in Animals and Plants (eds Asard, H. et al.) 35 (Taylor & Francis, New York, 2004).
doi: 10.1201/9780203500002-3
Hishikawa, D., Hashidate, T., Shimizu, T. & Shindou, H. Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells. J. Lipid Res. 55(5), 799–807. https://doi.org/10.1194/jlr.R046094 (2014).
doi: 10.1194/jlr.R046094
pubmed: 24646950
pmcid: 3995458
Sivaprakasam, S., Prasad, P. D. & Singh, N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacol. Ther. 164, 144–151. https://doi.org/10.1016/j.pharmthera.2016.04.007 (2016).
doi: 10.1016/j.pharmthera.2016.04.007
pubmed: 27113407
pmcid: 4942363
Hooper, L. et al. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst. Rev. 5(5), CD011737. https://doi.org/10.1002/14651858.CD011737.pub2 (2020).
doi: 10.1002/14651858.CD011737.pub2
pubmed: 32428300
Siri-Tarino, P. W., Sun, Q., Hu, F. B. & Krauss, R. M. Saturated fat, carbohydrate, and cardiovascular disease. Am. J. Clin. Nutr. 91(3), 502–509. https://doi.org/10.3945/ajcn.2008.26285 (2010).
doi: 10.3945/ajcn.2008.26285
pubmed: 20089734
pmcid: 2824150
Bolsoni-Lopes, A. et al. Palmitoleic acid (n-7) increases white adipocytes GLUT4 content and glucose uptake in association with AMPK activation. Lipids Health Dis. 20(13), 199. https://doi.org/10.1186/1476-511X-13-199 (2014).
doi: 10.1186/1476-511X-13-199
Cruz, M. M. et al. Palmitoleic acid (16:1n7) increases oxygen consumption, fatty acid oxidation and ATP content in white adipocytes. Lipids Health Dis. 17(1), 55. https://doi.org/10.1186/s12944-018-0710-z (2018).
doi: 10.1186/s12944-018-0710-z
pubmed: 29554895
pmcid: 5859716
Alves, S. P., Marcelino, C., Portugal, P. V. & Bessa, R. J. Short communication: The nature of heptadecenoic acid in ruminant fats. J. Dairy Sci. 89(1), 170–173. https://doi.org/10.3168/jds.S0022-0302(06)72081-1 (2006) (PMID: 16357280).
doi: 10.3168/jds.S0022-0302(06)72081-1
pubmed: 16357280
Amigo, J. M., Skov, T., Bro, R., Coello, J. & Maspoch, S. Solving GC-MS problems with PARAFAC2. TrAC Trends Anal. Chem. 27, 714–725. https://doi.org/10.1016/j.trac.2008.05.011 (2008).
doi: 10.1016/j.trac.2008.05.011
Giebelhaus, R. T., Sorochan Armstrong, M. D., de la Mata, A. P. & Harynuk, J. J. Untargeted region of interest selection for gas chromatography–mass spectrometry data using a pseudo F-ratio moving window. J. Chromatogr. A 1682, 463499. https://doi.org/10.1016/j.chroma.2022.463499 (2022).
doi: 10.1016/j.chroma.2022.463499
pubmed: 36126562
Giebelhaus, R. T., Erland, L. A. E. & Murch, S. J. HormonomicsDB: A novel workflow for the untargeted analysis of plant growth regulators and hormones. F1000Research 11, 119 (2022).
doi: 10.12688/f1000research.124194.1
Monnerie, S. et al. Metabolomic and lipidomic signatures of metabolic syndrome and its physiological components in adults: A systematic review. Sci. Rep. 10(1), 669. https://doi.org/10.1038/s41598-019-56909-7 (2020).
doi: 10.1038/s41598-019-56909-7
pubmed: 31959772
pmcid: 6971076
Kadowaki, T. et al. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. Diabetes Obes. Metab. 24(12), 2283–2296. https://doi.org/10.1111/dom.14829 (2022).
doi: 10.1111/dom.14829
pubmed: 35929483
pmcid: 9804928
National Heart, Lung, and Blood Institute (NHLBI). What is metabolic syndrome? https://www.nhlbi.nih.gov/health/metabolic-syndrome#:~:text=Metabolic%20syndrome%20is%20a%20group,also%20called%20insulin%20resistance%20syndrome . Last 18 May 2022.
R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/
Rubio, C. P., Martinez-Subiela, S., Hernández-Ruiz, J., Tvarijonaviciute, A. & Ceron, J. J. Analytical validation of an automated assay for ferric-reducing ability of plasma in dog serum. J. Vet. Diagn. Invest. 29(4), 574–578. https://doi.org/10.1177/1040638717693883 (2017).
doi: 10.1177/1040638717693883
pubmed: 28424022
Johnson, M. C. Hyperlipidemia disorders in dogs. Compend. Contin. Educat. Pract. Vet. 27, 361–364 (2005).
Littman, M. P. Spontaneous systemic hypertension in 24 cats. J. Vet. Intern. Med. 8(2), 79–86. https://doi.org/10.1111/j.1939-1676.1994.tb03202.x (1994). PMID: 8046680.
Jocelyn, P. C. Spectrophotometric assay of thiols. Methods Enzymol. 143, 44–67. https://doi.org/10.1016/0076-6879(87)43013-9 (1987). PMID: 3657559.